Table 1 Clinicopathological characteristics
From: Oncologic outcome of colon cancer with perforation and obstruction
Perforation (n = 32) | Obstruction (n = 22) | P-value | |
|---|---|---|---|
Age, y | 67.6 ± 15.2 | 64.1 ± 15.9 | 0.486 |
Sex | 0.501 | ||
Male | 23 (72%) | 15 (68%) | |
Female | 9 (28%) | 7 (32%) | |
Follow-up, months | 26.2 ± 21.6 | 26.6 ± 19.8 | 0.892 |
Location | 0.895 | ||
Rt sided colon | 10 (28%) | 6 (25%) | |
Lt-sided colon | 22 (61%) | 16 (67%) | |
Stage | 0.221 | ||
II | 13 (41%) | 4(18%) | |
III | 12 (37%) | 11 (50%) | |
IV | 7 (22%) | 7 (32%) | |
T stage | 0.569 | ||
3 | 15 (47%) | 14 (64%) | |
4a | 13 (41%) | 6 (27%) | |
4b | 4 (12%) | 2 (9%) | |
N stage | 0.236 | ||
0 | 14 (44%) | 5 (23%) | |
1 | 10 (31%) | 11 (50%) | |
2 | 8 (25%) | 6 (27%) | |
M stage | 0.420 | ||
0 | 25 (78%) | 15 (68%) | |
1a | 4 (12%) | 5 (23%) | |
1b | 1 (3%) | 0 (0%) | |
1c | 2 (6%) | 2 (9%) | |
Retrieved lymph nodes | 24 ± 10 | 24 ± 9 | 0.560 |
OP name | 0.107 | ||
Rt.hemicolectomy | 9 (36%) | 6 (40%) | |
Ant.resection | 3 (12%) | 1 (7%) | |
Low. Ant. Resection | 0 (0% | 1 (7%) | |
Lt. hemicolectomy | 1 (4%) | 3( 20%) | |
Total colectomy | 1 (4%) | 2 (13%) | |
Hartmann's operation | 11 (44%) | 2 (13%) | |
Complication | 0.025* | ||
No | 18 (56%) | 18 (82%) | |
Wound complication | 7 (22%) | 0 (0%) | |
Pneumonia | 1 (3%) | 2 (9%) | |
Others | 6 (19%) | 2 (9%) | |
Tumor size, cm | 5.5 ± 2.2 | 5.2 ± 1.6 | 0.506 |
Histologic grade | 0.019* | ||
Well, moderate | 22 (69%) | 21 (95%) | |
Poor, mucinous, others | 10 (31%) | 1 (5%) | |
LVI, positive | 18 (56%) | 13 (59%) | 0.593 |
PNI, positive | 11 (34%) | 10 (45%) | 0.746 |
MLH1, positive | 30 (94%) | 17 (77%) | 0.071 |
MSH2, positive | 31 (97%) | 17 (77%) | 0.036* |
KRAS mutant | 12 (37%) | 11 (50%) | 0.222 |
ICU stay (Days) | 4.9 ± 9 | 0.9 ± 1.1 | 0.018* |
Adjuvant chemotherapy | 0.286 | ||
No | 14 (44%) | 5 (23%) | |
Yes | 16 (50%) | 16 (73%) | |
Unknown | 2 (6%) | 1 (4%) | |
Tumor recurrence rate, % (except stage IV) | 9/25 (36%) | 1/15 (7%) | 0.040* |
Recurred tumor treatment | 0.423 | ||
No | 1 | 0 | |
Chemotherapy | 5 | 0 | |
Operation | 2 | 1 | |
Radiation | 1 | 0 | |
Recurrence sites, % (except stage IV) | 0.092 | ||
Local | 2/25 (8%) | 0 (0%) | |
Systemic | 7/25 (28%) | 1 (7%) | |
No | 16 (64%) | 14 (93%) |